



WE CLAIM:

1. A compound of formula (Ia), formula (Ib), formula (IIa) or formula (IIb):



Formula (I)




Formula (II)


or a pharmaceutically acceptable salt thereof:

wherein:

m is 0, 1, 2 or 3;



is selected from the group consisting of:



each R^1 is independently halogen, -CN, C_1 - C_3 alkyl, haloalkyl, alkyl-OH, $-N(R^4)_2$, $-NR^4C(O)C_1$ - C_3 alkyl, -OH, -O-alkyl, or cycloalkyl;


R^2 is H or halogen;

R^3 is H, halogen or C_1 - C_3 alkyl;


each R^4 is independently H or C_1 - C_3 alkyl; and

Y is CH or N.


~~2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein~~



~~is selected from the group consisting of:~~



32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein



43. The compound of claim 32, or a pharmaceutically acceptable salt thereof, wherein m is one.

54. The compound of claim 1, wherein R^1 is chlorine or fluorine.

65. The compound of claim 4, wherein R^1 is trifluoromethyl.

76. The compound of claim 1, wherein the each R^4 group of the $-N(R^4)_2$ is hydrogen.

87. The compound of claim 1, wherein the each R^4 group of the $-N(R^4)_2$ is C1-C3 alkyl.

98. The compound of claim 1, wherein R^1 is hydroxymethyl.


109. The compound of claim 1, wherein R^1 is cyclopropyl.

~~41~~10. The compound of claim 3, wherein m is two and each R¹ is independently cyano, halogen, C₁-C₃ alkyl or cycloalkyl.

~~42~~11. The compound of claim ~~41~~10, wherein each R¹ is halogen.

~~43~~12. The compound of claim ~~41~~10, wherein one R¹ is cyano and the other R¹ is hydroxyl, hydroxyalkyl, halogen, haloalkyl, alkoxy, Q-C₁-C₃ alkyl, -N(R⁴)₂, -NR⁴C(O)C₁-C₃ alkyl or cycloalkyl.

~~44~~13. The compound of claim 1, wherein



each R¹ is independently H or CH₃.

~~45~~14. The compound of claim ~~44~~13, wherein each R¹ is methyl.

~~46~~15. The compound according to any one of claims 1-~~45~~14, wherein R² is halogen.


~~47~~16. The compound of claim ~~46~~15, wherein the halogen is chlorine.


~~48~~17. The compound according to any one of claims 1-~~47~~16, wherein R³ is halogen or C₁-C₃ alkyl.

1918. The compound of claim **1917**, wherein the halogen is fluorine.

2019. The compound of claim **1917**, wherein the C₁-C₃ alkyl is methyl.

2120. ~~The compound of claim 1, wherein the A~~ compound which is selected from the group consisting of:





and pharmaceutically acceptable salts thereof.

~~21~~22. A pharmaceutical composition, comprising an effective amount of a compound according to any one of claims 1-~~21~~20, and a pharmaceutically acceptable excipient.

~~23~~22. Use of a therapeutically effective amount of a compound of claim 1 in the manufacture of a medicament for treating a condition in which inhibition of ~~inhibiting~~ ROCK activity in a patient is desired~~cell, wherein the cell is to be contacted with the compound.~~

~~24. The use of claim 23, wherein the contacting occurs in vivo.~~

~~25~~23. The use of claim ~~23 or~~ 24~~22~~, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.

~~26~~24. The use of claim ~~25~~ 23, wherein the therapeutically effective amount of the compound is between 0.1 to 100 mg/kg per day.

~~27~~25. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating cerebral cavernous malformation syndrome (CCM) in a patient.

~~28~~26. The use of Claim ~~27~~ 25, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.

- ~~29~~27. The use of Claim ~~28~~26, wherein the therapeutically effective amount of the compound is between 0.1 to 100 mg/kg per day.
- ~~30~~28. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating a cardiovascular disease associated with increased vasotension in a patient in need thereof.
- ~~31~~29. The use of claim ~~30~~28, wherein the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina or erectile dysfunction.
- ~~32~~30. Use of a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents, in the manufacture of a medicament for treating diseases involving elevated non-vascular smooth muscle contractility in a patient in need thereof.
- ~~33~~31. The use of claim ~~32~~30, wherein the disease involving elevated non-vascular smooth muscle contractility is asthma or glaucoma.